Application of biochemical markers in development of drugs for treatment of osteoarthritis

Biomarkers

Volumn 15, Issue 1, 2010, Pages 1-19

  Qvist, Per ^a   Christiansen, Claus ^a   Karsdal, Morten A ^a   Madsen, Suzi Høgh ^a   Sondergaard, Bodil Cecilie ^a   Bay Jensen, Anne Christine ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Biochemical markers; Joint diseases; Osteoarthritis

Indexed keywords

AGGRECAN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; HYALURONIC ACID; OSTEOCALCIN; OSTEONECTIN; PROCOLLAGEN C PROTEINASE;

BONE TURNOVER; DISEASE COURSE; DRUG RESEARCH; OSTEOARTHRITIS; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; DRUG DISCOVERY; HUMANS; OSTEOARTHRITIS;

EID: 75749139651     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903295873     Document Type: Review

References (154)

1. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De PL, Vanhaelst L and Reginster JY. (2004). Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12:263-268
2. Abramson S, Krasnokutsky S. (2006). Biomarkers in osteoarthritis. Bull NYU Hosp Jt Dis 64:77-81.
3. Akimoto S, Furuya Y, Akakura K, Shimazaki J, Ito H. (1997). Influence of osteoarthritis on serum marker levels of bone formation and resorption in patients with benign prostatic hypertrophy. Int J Urol 4:580-582
4. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J and Largo R. (2008). Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage 16:1484-1493
5. Andersson ML, Thorstensson CA, Roos EM, Petersson IF, Heinegard D, Saxne T. (2006). Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord 7:98.
6. Archer CW, Francis-West P. (2003). The chondrocyte. Int J Biochem Cell Biol 35:401-404
7. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegard D, Jordan JM, Kepler TB, Lane NE. (2006). Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723-727
8. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. (2005). Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 64:1263-1267
9. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. (2002). Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46:3178-3184
10. Bevilacqua M, Devogelaer JP, Righini V, Famaey JP, Manicourt DH. (2004). Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int J Clin Pract Suppl 13-19.
11. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Wart HV, Poole AR. (1997). Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99:1534-1545
12. Bingham CO III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. (2006). Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54:3494-3507
13. Bjarnason NH, Christiansen C. (2000). Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561-569 (Pubitemid 30301647)
14. Bondeson J, Wainwright S, Hughes C, Caterson B. (2008). The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 26:139-145
15. Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. (2008). N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. Clin Chem 54:1149-1157
16. Chaganti RK, Kelman A, Lui L, Yao W, Javaid MK, Bauer D, Nevitt M, Lane NE;Study of Osteoporotic Fractures Research Group Sof. (2008). Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage 16:566-571
17. Charni N, Desmarais S, Bay-Jensen A, Delaisse JM, Percival MD, Garnero P. (2008). The type II collagen fragments Helix-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation. Osteoarthritis Cartilage 16:1183-1191
18. Charni-Ben TN, Richardot P, Toh L, Marotte H, Bay-Jensen AC, Miossec P, Garnero P. (2009). Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis. Ann Rheum Dis 68:451-452
19. Chopin F, Garnero P, le HA, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T. (2008). Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353-357
20. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist P. (2001). Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29:209-215
21. Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J, Bruyere O, Deroisy R, Reginster JY. (2004). Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22:36-42.
22. Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM. (2005). Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 32: 896-902.
23. Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM. (2009). Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 60:1372-1380
24. Cicuttini FM, Jones G, Forbes A, Wluka AE. (2004). Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 63:1124-1127
25. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, Kraus VB. (1999). Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 42:2356-2364
26. Conrozier T, Saxne T, Fan CS, Mathieu P, Tron AM, Heinegard D, Vignon E. (1998). Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 57:527-532
27. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. (2009). Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 17:384-389
28. Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, Crielaard JM and Henrotin Y. (2008). One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67:168-174
29. Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. (2005). One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13:1059-1065
30. Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ, Poole AR. (2008). Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. Am J Pathol 1:161-169
31. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, Mezes PS, Pelletier JP, Otterness IG. (2001). Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 247:25-34.
32. Drees P, Decking J, Ghezel-Ahmadi V, Delank KS, Wilhelm B, Eckardt A. (2005). [The common occurrence of osteoarthritis and osteoporosis and the value of markers of bone turnover]. Z Rheumatol 64:488-498
33. Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, Dragomir AD, Helmick CG, Hochberg MC, Jordan JM. (2005). Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 52:105-111
34. Elomaa I, Virkkunen P, Risteli L, Risteli J. (1992). Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66:337-341
35. Emrani PS, Katz JN, Kessler CL, Reichmann WM, Wright EA, McAlindon TE, Losina E. (2008). Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis. Osteoarthritis Cartilage 16:873-882
36. Eyre DR, Weis MA. (2009). The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. Osteoarthritis Cartilage 17:423-426
37. Felson DT. (2004). An update on the pathogenesis and epidemiology of osteoarthritis 17. Radiol Clin North Am 42:1-9, v.
38. Felson DT, Neogi T. (2004). Osteoarthritis: is it a disease of cartilage or of bone? 21. Arthritis Rheum 50:341-344
39. Fex E, Eberhardt K, Saxne T. (1997). Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 36:1161-1165
40. Forsblad dH, Christgau S, Mattsson LA, Saxne T, Ohlsson C, Nordborg E, Carlsten H. (2004). Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res Ther 6:R457-R468.
41. Fosang AJ, Stanton H, Little CB, Atley LM. (2003). Neoepitopes as biomarkers of cartilage catabolism. Inflamm Res 52:277-282
42. Garnero P. (2006a). Biochemical markers in osteoarthritis: will they measure up? Nat Clin Pract Rheumatol 2:116-117 (Pubitemid 43771815)
43. Garnero P. (2006b). Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 8:37-44.
44. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO III. (2008a). Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16:660-666
45. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD. (2002). Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613-2624
46. Garnero P, Borel O, Delmas PD. (2001a). Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702.
47. Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD. (1998). Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563-569
48. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM. (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867
49. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. (1996). Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538 (Pubitemid 26331009)
50. Garnero P, Mazieres B, Gueguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Salles JP, Vignon E, Dougados M. (2005a). Crosssectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 32:697-703.
51. Garnero P, Peterfy C, Zaim S, Schoenharting M. (2005b). Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 52:2822-2829
52. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. (2001b). Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60:619-626
53. Garnero P, Rousseau J-C, Delmas PD. (2000a). Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 43:953-968
54. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. (2000b). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
55. Garnero P, Vergnaud P, Hoyle N. (2008b). Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188-196
56. Gendron C, Kashiwagi M, Lim NH, Enghild JJ, Thogersen IB, Hughes C, Caterson B, Nagase H. (2007). Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 282:18294-18306
57. Georges C, Vigneron H, Ayral X, Listrat V, Ravaud P, Dougados M, Sharif M, Dieppe P, Saxne T. (1997). Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. Arthritis Rheum 40:590-591
58. Gineyts E, Garnero P and Delmas PD. (2001). Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 40:315-323
59. Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, Garnero P, Delmas PD. (2004). Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 63:857-861
60. Glant TT, Mikecz K, Roughley PJ, Buzas E, Poole AR. (1986). Agerelated changes in protein-related epitopes of human articularcartilage proteoglycans. Biochem J 236:71-75 (Pubitemid 16095514)
61. Goldring SR. (2009). Role of bone in osteoarthritis pathogenesis. Med Clin North Am 93:25-35, xv.
62. Gressner OA, Weiskirchen R, Gressner AM. (2007). Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 11:1031-1051
63. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. (1992). A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258
64. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong le T. (2004). The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50:1193-1206
65. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong le T. (2006). Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38:234-243
66. Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ. (2006). Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 14:1189-1195
67. Henrotin Y, Addison S, Kraus V, Deberg M. (2007). Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 19:444-450
68. Henrotin Y, Deberg M, Dubuc JE, Quettier E, Christgau S, Reginster JY. (2004). Type II collagen peptides for measuring cartilage degradation. Biorheology 41:543-547
69. Hunter DJ, LaValley M, Li J, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D, Guermazi A, Gale D, Totterman S, Felson DT. (2008). Biochemical markers of bone turnover and their association with bone marrow lesions. Arthritis Res Ther 10:R102.
70. Hunter DJ, Li J, LaValley M, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D, Guermazi A, Gale D, Felson DT. (2007). Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9:R108.
71. Hunter DJ and Spector TD. (2003). The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 5:15-19.
72. Hurter K, Spreng D, Rytz U, Schawalder P, Ott-Knusel F, Schmokel H. (2005). Measurements of C-reactive protein in serum and lactate dehydrogenase in serum and synovial fluid of patients with osteoarthritis. Vet J 169:281-285
73. Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, Theobald M, Lafeber FP. (2009). The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 60:290-298
74. Johansen JS, Jensen HS, Price PA. (1993). A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 32:949-955
75. Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, Hochberg MC, Helmick CG, Kraus VB. (2003). Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 48:675-681
76. Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, Delmas PD, Cooper C, Arden NK. (2006). Urinary CTX-II and glucosyl-galactosyl- pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 65:871-877
77. Jung M, Christgau S, Lukoschek M, Henriksen D, Richter W. (2004). Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 71:70-76
78. Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K. (2004). Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci 34:330-335
79. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C. (2008). Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 16:638-646
80. Kellgren JH, Lawrence JS. (1957). Radiological assessment of rheumatoid arthritis. Ann Rheum Dis 16:485-493
81. Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T. (2008). Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 18:15-22.
82. Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. (2006). Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 54:2496-2504
83. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. (2007). Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849-853
84. Krasnokutsky S, Samuels J, Abramson SB. (2007). Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 65:222-228
85. Kraus VB. (2006). Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Pract Res Clin Rheumatol 20:69-80.
86. Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD. (2007). Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, doubleblind, placebo-controlled study. Arthritis Res Ther 9:R109.
87. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. (2006). The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15:32-38
88. Lein M, Miller K, Wirth M, Weissbach L, May C, Schmidt K, Haus U, Schrader M, Jung K. (2009). Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate69:624-632
89. Li MG, Thorsen K, Nilsson KG. (2004). Increased bone turnover as reflected by biochemical markers in patients with potentially unstable fixation of the tibial component. Arch Orthop Trauma Surg 124:404-409
90. Lohmander LS, Atley LM, Pietka TA, Eyre DR. (2003). The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 48:3130-3139
91. Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, Lane KA. (2005). Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 52:3160-3167
92. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. (2006). Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54:3205-3211
93. Manicourt DH, Bevilacqua M, Righini V, Famaey JP, Devogelaer JP. (2005). Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 6:261-271
94. Marotte H, Gineyts E, Miossec P, Delmas PD. (2008). Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 68:1197-1200
95. Mazieres B, Garnero P, Gueguen A, Abbal M, Berdah L, Lequesne M, Nguyen M, Salles JP, Vignon E, Dougados M. (2006). Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65:354-359
96. Mazieres B, Hucher M, Zaim M, Garnero P. (2007). Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 66:639-645
97. Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T. (2006). Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 33:1147-1151
98. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. (1996). Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42:947-954
99. Melkko J, Niemi S, Risteli L, Risteli J. (1990). Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36:1328-1332
100. Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand MP, DeGroot J, Slagboom PE. (2006). Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 65:360-365
101. Miller GD, Nicklas BJ, Davis CC, Ambrosius WT, Loeser RF, Messier SP. (2004). Is serum leptin related to physical function and is it modifiable through weight loss and exercise in older adults with knee osteoarthritis? Int J Obes Relat Metab Disord 28:1383-1390
102. Miller GD, Nicklas BJ, Loeser RF. (2008). Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 56:644-651
103. Millward-Sadler SJ, Salter DM. (2004). Integrin-dependent signal cascades in chondrocyte mechanotransduction. Ann Biomed Eng 32:435-446
104. Murphy G, Nagase H. (2008). Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4:128-135
105. Nagase H, Kashiwagi M. (2003). Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 5:94-103.
106. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, Fraser GL, Brooks E, Tanzer M, Rosenberg LC, Dieppe P, Robin PA. (1998). Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102:2115-2125
107. Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, Hein GE, Karsdal MA, Qvist P. (2007). Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15:335-342
108. Otterness IG, Brandt KD, Le Graverand MP, Mazzuca SA. (2007). Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. Arthritis Rheum 56:3644-3649
109. Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, Sculco TP, Crow MK. (2007). Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 15:516-523
110. Penninx BW, Abbas H, Ambrosius W, Nicklas BJ, Davis C, Messier SP, Pahor M. (2004). Inflammatory markers and physical function among older adults with knee osteoarthritis. J Rheumatol 31:2027-2031 (Pubitemid 39336730)
111. Pessis E, Drape JL, Ravaud P, Chevrot A, Dougados M, Ayral X. (2003). Assessment of progression in knee osteoarthritis: results of a 1 year study comparing arthroscopy and MRI. Osteoarthritis Cartilage 11:361-369
112. Peterfy CG, Guermazi A, Zaim S, Tirman PF, Miaux Y, White D, Kothari M, Lu Y, Fye K, Zhao S, Genant HK. (2004). Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12:177-190
113. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. (2004). The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294:145-153
114. Popko J, Zalewska A, Sierakowski S, Macias T, Knas M, Zwierz K, Sredzinska K. (2005). [Activity of N-acetylo-betahexosamninidase in joint fluid from knee and serum of patients with rheumatoid arthritis and osteoarthritis]. Przegl Lek 62:650-652
115. Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S. (2006). Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 14:702-713
116. Pulai JI, Chen H, Im HJ, Kumar S, Hanning C, Hegde PS, Loeser RF. (2005). NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 174:5781-5788
117. Quintana DJ, Garnero P, Huebner JL, Charni-Ben TN, Kraus VB. (2008). PIIANP and HELIXII diurnal variation. Osteoarthritis Cartilage 16:1192-1195
118. Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA. (2008). The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res 58:1-7.
119. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. (2002). Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57-61.
120. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA. (2004). A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50:2471-2478
121. Richardot P, Charni-Ben Tabassi N, Toh L, Marotte H, Bay-Jensen AC, Miossec P, Garnero P. (2009). Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis Cartilage May 12 [Epub ahead of print].
122. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. (1988). Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clin Chem 34:715-718 (Pubitemid 18129776)
123. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. (1998). Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-2289
124. Rousseau JC and Delmas PD. (2007). Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3:346-356
125. Rousseau JC, Sandell LJ, Delmas PD, Garnero P. (2004a). Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. Methods Mol Med 101:25-37.
126. Rousseau JC, Sumer EU, Hein G, Sondergaard BC, Madsen S, Pedersen C, Neumann T, Mueller A, Qvist P, Delmas P, Karsdal MA. (2008). Patients with Rheumatoid Arthritis have an altered circulatory Aggrecan Profile. BMC Musculoskelet Disord 9:74.
127. Rousseau J-C, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, Delmas PD. (2004b). Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 12:440-447
128. Ryu J, Towle CA and Treadwell BV. (1982). Characterisation of human articular cartilage link proteins from normal and osteoarthritic cartilage. Ann Rheum Dis 41:164-167
129. Salminen-Mankonen HJ, Morko J, Vuorio E. (2007). Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315-323
130. Samuels J, Krasnokutsky S, Abramson SB. (2008). Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 66:244-250
131. Sandy JD. (2006). A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis. Osteoarthritis Cartilage 14:95-100.
132. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J. (2000). Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367-373
133. Saxne T, Heinegard D. (1992). Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583-591
134. Scanzello CR, Umoh E, Pessler F, az-Torne C, Miles T, Dicarlo E, Potter HG, Mandl L, Marx R, Rodeo S, Goldring SR, Crow MK. (2009). Local cytokine profiles in knee osteoarthritis: elevated synovial fluid interleukin-15 differentiates early from end-stage disease. Osteoarthritis Cartilage 17:1040-1048
135. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, Qvist P, Karsdal MA. (2005). In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553-580
136. Schmidt-Rohlfing B, Thomsen M, Niedhart C, Wirtz DC, Schneider U. (2002). Correlation of bone and cartilage markers in the synovial fluid with the degree of osteoarthritis. Rheumatol Int 21:193-199
137. Sennels H, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, Peters N, Colic A, Grau K, Jacobsen S. (2008). Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 37:241-247
138. Sharaki OA, El-Guiziry DA, bou-Zeid AA, El-Noueam KI, Helal AE, Gaballah AE. (2004). Clinical usefulness of basic fibroblast growth factor and E-selectin in patients with rheumatoid arthritis. Egypt J Immunol 11:91-100.
139. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P. (2007). A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford) 46:938-943
140. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegard D, Dieppe PA. (1995). Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 34:306-310
141. Shen H, Sprott H, Aeschlimann A, Gay RE, Michel BA, Gay S, Sprott H. (2006). Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology 45:765-770
142. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM. (2005). Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7:R625-R633.
143. Spector TD, Reneland RH, Mah S, Valdes AM, Hart DJ, Kammerer S, Langdown M, Hoyal CR, Atienza J, Doherty M, Rahman P, Nelson MR, Braun A. (2006). Association between a variation in LRCH1 and knee osteoarthritis: a genome-wide single-nucleotide polymorphism association study using DNA pooling. Arthritis Rheum 54:524-532
144. Sugimoto H, Yamada H, Terada N, Kanaji A, Kato S, Date H, Ichinose H, Miyazaki K. (2006). Intraarticular injection of high molecular weight hyaluronan for osteoarthritis of the knee -prediction of effectiveness with biological markers. J Rheumatol 33:2527.
145. Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P. (2006). Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 11:485-506.
146. Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, Christiansen C, Qvist P. (2007). MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 15:212-221
147. Valdes AM, Doherty M, Spector TD. (2008). The additive effect of individual genes in predicting risk of knee osteoarthritis. Ann Rheum Dis 67:124-127
148. Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP. (2006). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 8:R31.
149. Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K. (2002). Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10:707-713
150. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. (2006). Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 95:506-514
151. Wilkinson JM, Stockley I, Hamer AJ, Barrington NA, Eastell R. (2003). Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res 21:529-534 (Pubitemid 36546820)
152. Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. (2004). How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis 63:264-268
153. Xu L, Peng H, Glasson S, Lee PL, Hu K, Ijiri K, Olsen BR, Goldring MB, Li Y. (2007). Increased expression of the collagen receptor discoidin domain receptor 2 in articular cartilage as a key event in the pathogenesis of osteoarthritis. Arthritis Rheum 56:2663-2673 (Pubitemid 47237284)
154. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, Duffin KL. (2008). Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 58:2420-2431